Skip to main content

Dalfopristin / quinupristin Pregnancy and Breastfeeding Warnings

Brand names: Synercid

Dalfopristin / quinupristin Pregnancy Warnings

Dalfopristin-quinupristin has been assigned to pregnancy category B by the FDA. Animal studies have revealed no evidence of impaired fertility or harm to the fetus. There are no controlled data in human pregnancy. The drug should only be given during pregnancy when need has been clearly established.

See references

Dalfopristin / quinupristin Breastfeeding Warnings

There are no data on the excretion of dalfopristin-quinupristin into human milk. It is excreted into rat milk. The manufacturer recommends caution when administering dalfopristin-quinupristin to nursing women.

See references

See also

References for pregnancy information

  1. (2001) "Product Information. Synercid (dalfopristin-quinupristin)." Rhone Poulenc Rorer

References for breastfeeding information

  1. (2001) "Product Information. Synercid (dalfopristin-quinupristin)." Rhone Poulenc Rorer

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer